戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 hibitor voxilaprevir (sofosbuvir-velpatasvir-voxilaprevir).
2  grazoprevir, paritaprevir, glecaprevir, and voxilaprevir.
3 ciated with treatment regimens that included voxilaprevir.
4 onstructural protein 3/4A protease inhibitor voxilaprevir.
5 ported more frequently by patients receiving voxilaprevir.
6  receiving 8 weeks of sofosbuvir-velpatasvir-voxilaprevir.
7 including NS3/4A protease inhibitors such as voxilaprevir.
8 itor velpatasvir, and the protease inhibitor voxilaprevir (150 patients) or matching placebo (150 pat
9  1:1 ratio to receive sofosbuvir-velpatasvir-voxilaprevir (163 patients) or sofosbuvir-velpatasvir (1
10 2, multicenter study, sofosbuvir-velpatasvir-voxilaprevir 400/100/100 mg daily was administered to ad
11                                   The median voxilaprevir 50% effective concentration against NS3 fro
12 I], 86-100) receiving sofosbuvir-velpatasvir-voxilaprevir alone and 24 of 25 (96%; 95% CI, 80-100) re
13 nly reported AEs with sofosbuvir-velpatasvir-voxilaprevir alone were diarrhea and bronchitis; and wit
14 response was 98% with sofosbuvir-velpatasvir-voxilaprevir and 90% with sofosbuvir-velpatasvir.
15 A protease inhibitors (PIs), glecaprevir and voxilaprevir, are highly effective across genotypes and
16 n clinical use-grazoprevir, glecaprevir, and voxilaprevir-are quinoxaline-based P2-P4 macrocycles and
17 response was 96% with sofosbuvir-velpatasvir-voxilaprevir, as compared with 0% with placebo.
18 elpatasvir) versus 3 (sofosbuvir-velpatasvir-voxilaprevir) DAAs.
19 156T dominated in genotype 1 glecaprevir and voxilaprevir escape variants, and pre-existing A156T fac
20                       Sofosbuvir-velpatasvir-voxilaprevir exposures were similar to those observed in
21 domly to groups given sofosbuvir-velpatasvir-voxilaprevir for 8 weeks or sofosbuvir-velpatasvir for 1
22 id not establish that sofosbuvir-velpatasvir-voxilaprevir for 8 weeks was noninferior to sofosbuvir-v
23  were enrolled in the sofosbuvir-velpatasvir-voxilaprevir group.
24  were enrolled in the sofosbuvir-velpatasvir-voxilaprevir group.
25 d pharmacokinetics of sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years with chronic
26  retreatment with sofosbuvir + velpatasvir + voxilaprevir in case of virological failure.
27 uvir/velpatasvir, and sofosbuvir/velpatasvir/voxilaprevir in cell culture, and how the HCV genome ada
28                These data support the use of voxilaprevir in combination with other DAAs in DAA-naive
29                                              Voxilaprevir is a direct-acting antiviral agent (DAA) th
30                       Sofosbuvir-velpatasvir-voxilaprevir is a pangenotypic regimen for chronic HCV i
31            In Europe, sofosbuvir-velpatasvir-voxilaprevir is also indicated in the absence of prior H
32 ngenotypic regimen of sofosbuvir-velpatasvir-voxilaprevir is highly efficacious and well-tolerated in
33                       Sofosbuvir/velpatasvir/voxilaprevir is recommended for hepatitis C virus (HCV)
34 n the USA and Europe, sofosbuvir-velpatasvir-voxilaprevir once daily for 12 weeks is indicated for ad
35  bronchitis; and with sofosbuvir-velpatasvir-voxilaprevir plus RBV were fatigue, anemia, gastroenteri
36 ration (FDA) approved sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) (Vosevi) fixed-dose combinati
37 alvage treatment with Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) achieved an SVR12 rate of >95
38 alvage treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) achieved an SVR12 rate of >95
39 s the pangenotypic NS3/4A protease inhibitor voxilaprevir (sofosbuvir-velpatasvir-voxilaprevir).
40                                              Voxilaprevir susceptibilities of HCV replicons with NS3
41                                          The voxilaprevir susceptibility of clinical and laboratory s
42 otease inhibitors had little to no impact on voxilaprevir susceptibility, except A156L, T, or V in ge
43                       Sofosbuvir/velpatasvir/voxilaprevir (SVV) is recommended as the first-line retr
44                       Sofosbuvir-velpatasvir-voxilaprevir taken for 12 weeks provided high rates of s
45 patients discontinued sofosbuvir-velpatasvir-voxilaprevir therapy because of an adverse event (AE).
46  an SVR to 8 weeks of sofosbuvir-velpatasvir-voxilaprevir; this did not meet the criterion to establi
47 riority of 8 weeks of sofosbuvir-velpatasvir-voxilaprevir to 12 weeks of sofosbuvir-velpatasvir using
48 pprovals such as Lorlatinib, glecaprevir, or voxilaprevir underline the clinical relevance of drug-li
49 d-dose combination of sofosbuvir-velpatasvir-voxilaprevir was well tolerated and effective at achievi
50 combination tablet of sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin (RBV) for 12 week